Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Trenbolone is a synthetic anabolic-androgenic steroid (AAS) derived from 19-nortestosterone (nandrolone). It was developed in France in the 1960s by Roussel-Uclaf and is one of the most potent anabolic compounds ever synthesized. Published data describe it as binding to the androgen receptor with approximately three times the affinity of testosterone PMID: 20138077.
Critically, trenbolone has never been approved for human therapeutic use in the United States, European Union, or any other major jurisdiction. Its only approved applications have been veterinary, specifically as a growth promoter (Finaplix, Synovex) in beef cattle production. All trenbolone encountered in human contexts derives from either veterinary product diverted from agricultural channels or, more commonly, unregulated producers producing it for non-medical use.
The trenbolone molecule itself has a short circulating half-life of approximately 6–8 hours once cleaved from the ester. The ester is purely a release-rate modifier.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Acetate | ~3 days |
| Enanthate | ~7–10 days |
| Hexahydrobenzylcarbonate (Parabolan) | ~14 days |
What it does
Main effects
- Very high androgen-receptor binding affinity: approximately 3× testosterone PMID: 20138077; among the highest of any AAS
- Pronounced muscle hypertrophy with strong protein synthesis and nitrogen retention
- Nutrient partitioning: favors muscle accretion over adipose; possible direct lipolytic activity
- No aromatization to estrogen: does not produce water retention or estrogen-mediated effects from itself
- Glucocorticoid receptor antagonism: contributes to anti-catabolic effects (mechanistic literature; limited human data)
- Reputation for dramatic body recomposition during cutting phases; basis of its non-medical popularity despite the severe side-effect profile
What to watch for
Common side effects
- Severe cardiovascular events: heart failure, myocardial infarction, ischemic stroke documented in young trenbolone users in case reports 2025 structured review
- Dramatic lipid changes: substantial HDL reduction and LDL elevation, typically worse than with testosterone
- Profound HPG axis suppression: among the most suppressive AAS; recovery often prolonged or incomplete
- Prolactin elevation via progesterone receptor activity: produces reduced libido, erectile dysfunction, and gynecomastia even without elevated estrogen
- Severe insomnia and night sweats: among the most consistently reported subjective effects
- Neuropsychiatric effects: aggression ("tren rage"), anxiety, depression; case reports of acute psychosis and delirium
- Pronounced erythrocytosis: hematocrit elevations exceeding 55% commonly reported
- "Tren cough": characteristic acute cough with metallic taste within seconds of injection
- Severe acne and accelerated scalp hair loss in predisposed users
- Unregulated supply chain risks: no legitimate human pharmaceutical source; all product is veterinary diversion or unregulated production
Key facts
Key facts worth knowing
- Trenbolone cannot aromatize to estrogen: the structural modifications inherited from nandrolone prevent aromatase from acting on the molecule.
- However, trenbolone is a progesterone receptor agonist. Acting through this pathway, it can elevate prolactin and cause gynecomastia even in the absence of estrogen elevation. This is a distinguishing feature from compounds like drostanolone, which also do not aromatize but do not have progestogenic activity.
- A 2025 structured review of 23 published case reports of trenbolone adverse effects found the most frequent serious complications involved the cardiovascular system (heart failure, myocardial infarction, ischemic stroke), hepatic system (cholestatic liver injury), renal system (nephropathy, acute kidney injury), and neuropsychiatric effects (psychosis, aggression, delirium). Structured review of trenbolone case reports 2025
- Trenbolone has been described in animal studies as having neurotoxic and genotoxic effects at concentrations relevant to non-medical use, with documented neurodegeneration and aggression-related behavioral changes in rodent models. Translation of these specific findings to humans is uncertain. Zelleroth et al. 2019, 2024
- There is no legitimate human pharmaceutical supply. Trenbolone encountered in non-medical contexts is either diverted veterinary product or unregulated production, which carries severe purity, sterility, and dosing accuracy concerns.
Legal status
Legal status
Schedule III controlled substance in the United States (DEA). No FDA approval for human use under any circumstance. Veterinary use is restricted to specific approved cattle implant products. WADA-prohibited at all times in competitive sport.